甲状腺激素受体相关蛋白15的研究进展  

Research Progress in Thyroid Hormone Receptor Interacting Protein 15

作　　者：王海波[1] 孟照辉[1] 

机构地区：[1]昆明医科大学第一附属医院心内科分子心血管病研究室,昆明650032

出　　处：《医学综述》2013年第14期2497-2501,共5页Medical Recapitulate

基　　金：国家自然科学基金(81160025);云南省中青年学术技术带头人后备人才资助项目(2011CI057);云南省教育厅重大专项(ZD2010007);云南省应用基础研究重点项目(2012FB005)

摘　　要：甲状腺激素受体相关蛋白15(TRIP15)是一个核受体家族的选择性转录共抑制子,参与构成COP9信号复合体,调节机体蛋白质的降解。TRIP15与涉及转录调节、细胞周期调控、DNA损伤修复的多种生物大分子相互作用,参与细胞增殖、分化、凋亡等重要生理过程,其表达调控的信号通路与肿瘤、脂质代谢紊乱及内分泌疾病的发生与发展密切相关。TRIP15具有复杂的蛋白质相互作用网络及多样的生物学功能,可能会成为疾病治疗的新靶点。Thyroid hormone receptor interacting protein 15（TRIP15） is a transcriptional co-repressor for selected nuclear receptor family and constitutes COP9 signalosome complex which involves in protein degradation. It also interacts with a number of molecules involved in transcription control,cell cycle modulation and DNA repair. These functional studies have revealed that TRIP15 engages in the vital cellular process such as proliferation,differentiation and apoptosis,thus associates with neoplasms,lipid metabolism disorders,endocrine disorders and so on. Though the function of TRIP15 is largely unknown,its complicated protein interacting network and multifunctional potentials may present a new target for medical intervention.

关 键 词：甲状腺激素受体相关蛋白15 转录共抑制子 核受体 COP9信号复合体 肿瘤 

分 类 号：R34[医药卫生—基础医学]